Evogene
EVGN
27 hedge funds and large institutions have $494K invested in Evogene in 2023 Q1 according to their latest regulatory filings, with 1 funds opening new positions, 6 increasing their positions, 8 reducing their positions, and 5 closing their positions.
282% more call options, than puts
Call options by funds: $42K | Put options by funds: $11K
0.07% less ownership
Funds ownership: 0.27% → 0.19% (-0.07%)
13% less funds holding
Funds holding: 31 → 27 (-4)
25% less repeat investments, than reductions
Existing positions increased: 6 | Existing positions reduced: 8
35% less capital invested
Capital invested by funds: $754K → $494K (-$260K)
80% less first-time investments, than exits
New positions opened: 1 | Existing positions closed: 5
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
+$46K |
| 2 |
Renaissance Technologies
New York
|
+$21.2K |
| 3 |
BNP Paribas Financial Markets
Paris,
France
|
+$3.28K |
| 4 |
Royal Bank of Canada
Toronto,
Ontario, Canada
|
+$2.67K |
| 5 |
LPL Financial
San Diego,
California
|
+$1.49K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SCM
Silverarc Capital Management
Boston,
Massachusetts
|
-$105K |
| 2 |
Bank of America
Charlotte,
North Carolina
|
-$88K |
| 3 |
Morgan Stanley
New York
|
-$49.8K |
| 4 |
Citadel Advisors
Miami,
Florida
|
-$20.5K |
| 5 |
CAG
Crestwood Advisors Group
Boston,
Massachusetts
|
-$9.8K |
EVGN Hedge Fund Activity: Q1 2023 in Review
27 of the 6,276 institutional investors tracked by Wall St. Rank reported a position in Evogene (EVGN) for Q1 2023, worth a combined $494K — down 35% from $754K a quarter earlier.
Sellers outnumbered buyers: 5 funds closed out of EVGN and 1 opened new positions — a net loss of 4 holders — while 8 trimmed existing stakes and 6 added.
The largest buyer was Millennium Management, adding an estimated $46K. The largest seller was Silverarc Capital Management, exiting entirely with an estimated $105K sold.
- 27 institutional investors held Evogene (EVGN) as of Q1 2023, down from 31 in Q4 2022.
- Funds reported $494K of Evogene stock for Q1 2023, down 35% quarter-over-quarter.
- 1 fund opened new Evogene positions in Q1 2023 and 5 closed out, a net change of -4 holders.
- The largest Evogene buyer in Q1 2023 was Millennium Management, an estimated $46K added.
- The largest Evogene seller in Q1 2023 was Silverarc Capital Management, an estimated $105K sold.
Based on aggregated 13F filings for Q1 2023.